Français
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Page 1 de 41 résultats
Method of controlling emesis caused by cisplatin in cancer chemotherapy
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
1. Field of Invention
Cisplatin (cis-dichlorodiammine platinum II) is one of the more effective drugs used in cancer chemotherapy; however, the resulting violent emesis interferes with acceptance of therapy by the patient. This invention relates to an improvement in the
Method for the management of cancer and cancer treatment-related comorbidities
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
TECHNICAL FIELD
The invention concerns a method for the management of cancer and treatment cancer comorbidities, including but not limited to cancer-related fatigue, cachexia, anorexia, pain, anemia, asthenia, depression, impaired cognitive function, loss of appetite, muscle weakness, nausea,
NK1 receptor antagonist
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
TECHNICAL FIELD
The present invention relates to NK.sub.1 receptor antagonist useful as medicaments.
More particularly, the present invention relates to NK.sub.1 receptor antagonist or pharmaceutically acceptable salts thereof which have substance P/neurokinin 1 (NK.sub.1) receptor antagonist
Ondansetron orally disintegrating tablets
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention generally relates to non-effervescent, solid dosage forms adapted for oral administration of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carb- azol-4-one (ondansetron) as an anti-emetic active
Cyclohexyl pyridine derivative
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
TECHNICAL FIELD
The present invention relates to cyclohexyl pyridine derivatives useful as medicaments.
More particularly, the present invention relates to cyclohexyl pyridine derivatives or pharmaceutically acceptable salts thereof which have substance P/neurokinin 1 (NK.sub.1) receptor antagonist
Cyclohexyl pyridine derivative
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
TECHNICAL FIELD
The present invention relates to cyclohexyl pyridine derivatives useful as medicaments.
More particularly, the present invention relates to cyclohexyl pyridine derivatives or pharmaceutically acceptable salts thereof which have substance P/neurokinin 1 (NK.sub.1) receptor antagonist
Pharmacologically active substituted benzamides
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
SUMMARY OF THE INVENTION
This invention relates to novel substituted benzamides of the formula ##STR2## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and A are as defined below, which are useful in the treatment of emesis, particularly chemotherapy-induced emesis, such as cisplatin treatment
Polynucleotides that encode the calcitonin gene-related peptide receptor coponent factor (HOUNDC44)
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
This invention relates, in part, to newly identified polynucleotides and polypeptides; variants and derivatives of the polynucleotides and polypeptides; processes for making the polynucleotides and the polypeptides, and their variants and derivatives; agonists and antagonists
Aprepitant L-proline solvates--compositions and cocrystals
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The invention relates to a new aprepritant compositions and crystalline compounds containing aprepitant. More particularly, the invention relates to solvated aprepitant L-proline solvate compositions, aprepitant L-proline solvate cocrystals, therapeutic uses of the aprepitant
Aprepitant L-proline composition and cocrystal
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The invention relates to a new aprepitant composition and a crystalline compound containing aprepitant, more particularly, the invention relates to an aprepitant L-proline composition, an aprepitant L-proline cocrystal, therapeutic uses of the aprepitant L-proline or the
ABHD6 and dual ABHD6/MGL inhibitors and their uses
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND
Cannabinoid receptors, CB1 and CB2, are part of the endocannabinoid system (ECS), which consists of cannabinoid receptors, endogenous endocannabinoids anandamide (AEA) and 2-arachindonoylglycerol (2-AG) and the hydrolytic enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol
Methods of screening for agonists and antagonists of the interaction between the human KIAA0001 receptor and ligands thereof
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
This invention relates to methods for discovering agonists and antagonists of the interaction between UDP-sugars (e.g.,UDP-glucose, UDP-galactose, UDP-glucuronic acid, and UDP-N-acetyl glucosamine) and their cellular receptor, human KIAA0001 receptor. The invention also
Ethynyl derivatives
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
The present invention relates to compounds of formula I
##STR00002## wherein Y is C--R.sup.1'; R.sup.1' is hydrogen or halogen; R.sup.1 is hydrogen or halogen; R.sup.2 is hydrogen, lower alkyl or phenyl; R.sup.4 is hydrogen or lower alkyl; or R.sup.2 and R.sup.4 may form together with the
Ethynyl derivatives
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
The present invention relates to compounds of formula I
##STR00001## wherein R.sup.1 is lower alkyl; R.sup.2 is phenyl or pyridinyl, wherein the N atom in the pyridinyl group may be in different positions; n is 0, 1 or 2; V/U are independently from each other O or CH.sub.2, wherein V and U cannot be
Ethynyl derivatives
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
The present invention relates to compounds of formula I
##STR00001## wherein Y is N or C--R.sup.1'; G is a 5 or 6-membered aromatic or heteroaromatic ring containing 0, 1, 2 or 3 heteroatoms, selected from the group consisting of phenyl, pyridinyl with different N-positions, imidazolyl, pyrazinyl,
La base de données d'herbes médicinales la plus complète soutenue par la science
- Fonctionne en 55 langues
- Cures à base de plantes soutenues par la science
- Reconnaissance des herbes par image
- Carte GPS interactive - étiquetez les herbes sur place (à venir)
- Lisez les publications scientifiques liées à votre recherche
- Rechercher les herbes médicinales par leurs effets
- Organisez vos intérêts et restez à jour avec les nouvelles recherches, essais cliniques et brevets
Tapez un symptôme ou une maladie et lisez des informations sur les herbes qui pourraient aider, tapez une herbe et voyez les maladies et symptômes contre lesquels elle est utilisée.
* Toutes les informations sont basées sur des recherches scientifiques publiées
